Selegiline in the management of apathy
following traumatic brain injury
by
Newburn G, Newburn D.
Rotorua Rehabilitation Clinic,
Rotorua, New Zealand.
dengil@xtra.co.nz
Brain Inj. 2005 Feb;19(2):149-54.

ABSTRACT

PRIMARY OBJECTIVE: To provide a brief review of apathy following traumatic brain injury (TBI) and describe the use of selegiline in a group of patients with this symptom. MAIN OUTCOME: Four patients are described who showed improvement in Apathy Evaluation Scale scores and functional improvement, following the use of selegiline. In each case, selegiline was well tolerated whereas methylphenidate was not. CONCLUSIONS: Selegiline shows potential for the management of apathy following TBI. This provides further evidence that impaired dopaminergic processes are prominent in the genesis of these symptoms. However, these findings require confirmation in controlled studies.

EMSAM
Antiaging compounds
Selegiline and the DAT
Selegiline and nitric oxide
Selegiline and life-expectancy
Selegiline for longer-lived flies
Selegiline: product information
Selegiline and (-)-BPAP in major depression

Refs
HOME
HedWeb
BLTC Research
Paradise-Engineering
Utopian Pharmacology
The Hedonistic Imperative
When Is It Best to Take Crack Cocaine?